Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

19.9%

29 terminated/withdrawn out of 146 trials

Success Rate

75.0%

-11.6% vs industry average

Late-Stage Pipeline

23%

34 trials in Phase 3/4

Results Transparency

2%

2 of 87 completed trials have results

Key Signals

15 recruiting2 with results28 terminated

Enrollment Performance

Analytics

Phase 2
75(54.0%)
Phase 3
34(24.5%)
Phase 1
24(17.3%)
N/A
6(4.3%)
139Total
Phase 2(75)
Phase 3(34)
Phase 1(24)
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (146)

Showing 20 of 146 trials
NCT06284122Phase 3Active Not Recruiting

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5

Role: collaborator

NCT07158489Phase 2Recruiting

Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

Role: lead

NCT06358573Phase 2Recruiting

Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

Role: lead

NCT07574047Phase 2Not Yet Recruiting

MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.

Role: lead

NCT07661927Phase 2Recruiting

Skipping Hormone Therapy in Low-Risk Early Breast Cancer

Role: collaborator

NCT07617610Recruiting

Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer

Role: lead

NCT07149649Phase 2Recruiting

Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT07365423Phase 2Recruiting

Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro)

Role: lead

NCT06401980Phase 2Recruiting

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Role: lead

NCT05904119Phase 3Recruiting

Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

Role: collaborator

NCT05815927Phase 3Recruiting

Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer

Role: collaborator

NCT07237256Phase 3Recruiting

Chemotherapy De-escalation in HR +, HER2-, Intermediate-risk Early Breast Cancer Treated With Adjuvant Ribociclib

Role: collaborator

NCT07593482Phase 2Not Yet Recruiting

Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.

Role: lead

NCT01101425Active Not Recruiting

Male Breast Cancer: Understanding the Biology for Improved Patient Care

Role: collaborator

NCT07020065Phase 2Recruiting

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Role: lead

NCT06114108Not ApplicableRecruiting

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

Role: lead

NCT04245514Phase 2Active Not Recruiting

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

Role: lead

NCT06090162Not ApplicableActive Not Recruiting

LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma

Role: lead

NCT04630730Phase 2Active Not Recruiting

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Role: lead

NCT03937843Phase 2Active Not Recruiting

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Role: lead